Safety Reporting of Clinical Trials of Investigational Medical Products (CTIMPs) for UK Health Departments' Research Ethics Service (RES)

Serious adverse reaction

A **serious adverse reaction** is an untoward and unintended response to an IMP at any dose, that:

a) results in death;
b) is life-threatening.
c) requires hospitalisation or prolongation of existing hospitalisation;
d) results in persistent or significant disability or incapacity; or
e) consists of a congenital abnormality or birth defect.

An **adverse reaction** is unexpected if its nature and severity are not consistent with the information about the medicinal product in question set out:

- In the case of a product with marketing authorisation, in the Summary of Product Characteristics for that product
- In the case of any other IMP, in the Investigators Brochure relating to the trial in question

Reporting date for periodic safety reports

Does the IMP have marketing authorisation in any EU member state?	**Reporting date**
Yes	The International Birth Date for the product
No	The date on which any trial of the IMP being conducted by the sponsor was first authorised by a competent authority in any EU member state

For more detailed guidance, see the European Commission guidance on adverse reaction reporting (ENTR/CT3) available from: http://ec.europa.eu/health/documents/eudralex/vol-10/index_en.htm

Reporting of individual SUSARs

	Who	When	What	How	To Whom
Reporting of individual SUSARs	Sponsor, sponsor's legal representative or Chief Investigator.	(a) or (b) must be reported within 7 days of the sponsor becoming aware of the event. Any additional information must be reported within 8 days of sending the first report. (c) (d) or (e) must be reported within 15 days of the sponsor becoming aware of the event.	Any SUSAR in the relevant trial in the UK.	RES Safety Report Form (CTIMPs), enclosing: SUSAR report (no form prescribed but should be in the format set out in the current version of *ICH Topic E2B – Clinical Safety Data Management).*	The REC which issued the favourable ethical opinion. REC Manager will acknowledge within 30 days.
Annual safety reporting	Sponsor, sponsor's legal representative or Chief Investigator.	Annually – within 60 days of reporting date.	List all worldwide SSARs in the reporting period, i.e. both expected and unexpected. Summarise any issues affecting safety of participants.	RES Safety Report Form (CTIMPs), All annual safety reports should be in the format for Development Safety Update Reports (DSUR) set out in the ICH E2F guideline (https://ich.org/page/efficacy-guidelines)	Each REC responsible for a trial of the IMP (use separate covering form for each).

	Who	When	What	How	To Whom
Urgent safety measures	Sponsor, sponsor's legal representative or Chief Investigator. Or exceptionally by local Principal Investigator (PI).	(i) Immediately (by telephone) (ii) Within 3 days (in writing).	Reasons for the urgent safety measures and the plan for further action.	(i) By telephone. (ii) Notice in writing.	The REC which issued the favourable ethical opinion.